1-12 of 12
Authors: Eddy Saad
Save search
Sort by
Journal Article

46 Radiological tumor burden is an independent risk factor for survival in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with first line immunotherapy (IO)-based regimens

PDF
Rashad Nawfal and others
The Oncologist, Volume 29, Issue Supplement_1, September 2024, Pages S25–S26, https://doi.org/10.1093/oncolo/oyae181.041
Published: 05 August 2024
Journal Article

20 Evaluating intermediate endpoints for overall survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors: an IMDC study

PDF
Renee Maria Saliby and others
The Oncologist, Volume 29, Issue Supplement_1, September 2024, Pages S8–S9, https://doi.org/10.1093/oncolo/oyae181.013
Published: 05 August 2024
Journal Article

22 Association of a germline single nucleotide polymorphism (SNP) in the interleukin-7 (IL7) gene with immune-related adverse events (irAEs)

PDF
Eddy Saad and others
The Oncologist, Volume 29, Issue Supplement_1, September 2024, Pages S1–S2, https://doi.org/10.1093/oncolo/oyae181.003
Published: 05 August 2024
Journal Article

49 Inhibition of AXL along with c-Met potentially halts resistance development in renal cell carcinoma

PDF
Marc Machaalani and others
The Oncologist, Volume 29, Issue Supplement_1, September 2024, Pages S27–S28, https://doi.org/10.1093/oncolo/oyae181.043
Published: 05 August 2024
Journal Article

35 Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC)

PDF
Justine Panian and others
The Oncologist, Volume 29, Issue Supplement_1, September 2024, Page S22, https://doi.org/10.1093/oncolo/oyae181.036
Published: 05 August 2024
Journal Article

44 Liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma

PDF
Karl Semaan and others
The Oncologist, Volume 29, Issue Supplement_1, September 2024, Pages S4–S5, https://doi.org/10.1093/oncolo/oyae181.006
Published: 05 August 2024
Journal Article

24 Applying genomic analysis to refine unclassified renal cell carcinoma

PDF
Emre Yekeduz and others
The Oncologist, Volume 29, Issue Supplement_1, September 2024, Page S20, https://doi.org/10.1093/oncolo/oyae181.032
Published: 05 August 2024
Journal Article

59 Risk Factors of Immune Related Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

PDF
Razane El Hajj Chehade and others
The Oncologist, Volume 29, Issue Supplement_1, September 2024, Page S1, https://doi.org/10.1093/oncolo/oyae181.051
Published: 05 August 2024
Journal Article

Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens

PDF
Eddy Saad and others
The Oncologist, Volume 29, Issue 8, August 2024, Pages 699–706, https://doi.org/10.1093/oncolo/oyae072
Published: 17 April 2024
Journal Article

Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic Neoplasms

PDF
Chris Labaki and others
The Oncologist, Volume 28, Issue Supplement_1, September 2023, Pages S7–S8, https://doi.org/10.1093/oncolo/oyad216.011
Published: 23 August 2023
Journal Article

Epigenomic profiling nominates master transcription factors (TFs) driving sarcomatoid differentiation (SD) of renal cell carcinoma (RCC)

PDF
Talal El Zarif and others
The Oncologist, Volume 28, Issue Supplement_1, September 2023, Page S8, https://doi.org/10.1093/oncolo/oyad216.012
Published: 23 August 2023
Journal Article

Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC)

PDF
Eddy Saad and others
The Oncologist, Volume 28, Issue Supplement_1, September 2023, Pages S4–S5, https://doi.org/10.1093/oncolo/oyad216.007
Published: 23 August 2023